Suddenly, a number of companies disclosed important positive and negative announcements in the morning (1229）
Bearish and positive announcement: performance to achieve substantial profits, equity pledge and centralized bidding to repurchase shares, etc.).
1. Kaizhong shares: the company added the concept of "Xiaomi car".
In 2023, it will once again win the GM GM Global Excellent Quality Merchant Award. In January 2023, it passed the audit of Chery electronic throttle new businessmen, and in July 2023, it passed the audit of Xiaomi Automobile's buffer block new businessmen.
Kaizhong's domestic market share of chassis suspension system shock absorbing components exceeds 30%, and the brake pedal of the company's self-developed quick-connect structure has been recognized by Geely, SAIC, Chery Automobile and other customers and achieved mass production.
2. Yabao Pharmaceutical: A favorable announcement on participating in the investment of new limited partners and capital increase of Hangzhou Huafang Fengbai Investment Management Partnership (Limited Partnership).
The company is committed to the research and development of innovative drugs, and the latest announcement, all partners reached a consensus and re-signed the "Partnership Agreement of Hangzhou Huafang Fengbai Investment Management Partnership (Limited Partnership)".
The new Hangzhou Fuyang Industry Investment Management became a limited partner of Huafang Fengbai, and the total subscription scale of Huafang Fengbai increased from 4500 million yuan to 500 million yuan. After the capital increase of Huafang Fengbai, the company accounted for 1111% changed to 1000%。
3. Zhewen Internet: The company's original shareholders holding more than 5% of the shares of the negative announcement of the results.
The company is the leading company in performance marketing, the latest announcement, the company received the "Notice Letter on the Implementation Results of the Plan" issued by Shandong Keda.
During the implementation period of the plan, Shandong Keda accumulated 14,683,600 shares of the company through centralized bidding transactions, accounting for 0 of the company's total share capital987216% of the time for this ** plan has expired.
4. CRRC: Important positive, announcement on the progress of the subsidiary's initiation of the establishment of Huayu High-tech Traffic Control Industry Chain Investment Partnership.
The company is mainly engaged in rail transit equipment and its extension industry, the latest announcement, the investment parties have signed the "partnership agreement" on the establishment of **, * has been registered in the administrative department for industry and commerce.
Pursuant to the Partnership Agreement signed by the parties. The total subscribed capital contribution of ** is 303,100 yuan, and CRRC Capital, a wholly-owned subsidiary of the company, subscribes 90,000 yuan as the ** limited partner.
5. Hengrui Pharmaceutical: news of important matters of the company.
The marketing authorization application submitted by the company was accepted by the XX Food and Drug Administration. This product is suitable for patients with moderate to severe active rheumatoid arthritis who have poor efficacy or intolerance to one or more traditional synthetic disease-modifying antirheumatic drugs.
Hengrui Pharmaceutical is one of the more than 20 leading manufacturers designated by the state, and camrelizumab is a humanized PD-1 monoclonal antibody independently developed by the company and with intellectual property rights.
Attention!The content of the article and the public information involved in the subject matter are summarized and do not constitute any basis for trading, and the investment risk is at your own risk.